Showing results (621-630 of 709) with videos related to

Sort By:
Pageof 71
Gastroenterology|October 14, 2018
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote ColitisYilang Tang, Sonja Reissig, Elke Glasmacher, et al.
International Journal of Cancer|October 15, 2013
High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancerNaohide Oue, Katsuhiro Anami, Aaron J Schetter, et al.
Scientific Reports|October 25, 2024
Different risk and protective factors predict change of planning ability in middle versus older ageJosef M Unterrainer, Julia Petersen, Peter Schmidt, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 19, 2012
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trialMarcus Schuchmann, Jens M Kittner, Jörg F Schlaak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2024
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular CarcinomaBruno Sangro, Peter R Galle, Robin Kate Kelley, et al.
Immunity|October 16, 2004
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signalingChristoph Becker, Massimo C Fantini, Christoph Schramm, et al.
The Journal of Clinical Investigation|June 7, 2008
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6Jonas Mudter, Lioubov Amoussina, Mirjam Schenk, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 20, 2020
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapiesAlimuddin Zumla, Fu-Sheng Wang, Giuseppe Ippolito, et al.
Oncotarget|February 1, 2018
Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesisJohanna Vollmar, Anja Lautem, Ellen Closs, et al.
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Pageof 71